Published in Breast Cancer Res on January 01, 2007
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med (2013) 2.54
Identification of CD44 as a surface biomarker for drug resistance by surface proteome signature technology. Mol Cancer Res (2011) 0.94
Herceptin resistance database for understanding mechanism of resistance in breast cancer patients. Sci Rep (2014) 0.87
Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma. J Clin Pathol (2010) 0.86
Chromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomas. Braz J Med Biol Res (2013) 0.83
Impact of polysomy 17 on HER2 testing of invasive breast cancer patients. Int J Clin Exp Pathol (2013) 0.76
Incorporating gold nanoclusters and target-directed liposomes as a synergistic amplified colorimetric sensor for HER2-positive breast cancer cell detection. Theranostics (2017) 0.75
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 13.81
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol (1999) 11.78
Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol (2003) 2.67
Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol (2002) 2.67
Increased HER2 with U.S. Food and Drug Administration-approved antibody. J Clin Oncol (1999) 2.48
Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol (2000) 2.41
The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. Oncologist (1998) 2.02
Best Practice No 176: Updated recommendations for HER2 testing in the UK. J Clin Pathol (2004) 1.90
Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol (2001) 1.76
Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res (2004) 1.46
Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study. Histopathology (2003) 1.23
Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol (2002) 1.18
Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer (2003) 1.17
Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther (2006) 1.03
Conference summary, Strategic Science symposium. Her-2/neu testing of breast cancer patients in clinical practice. Arch Pathol Lab Med (2003) 1.02
Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study. Breast Cancer Res (2007) 1.01
Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer. Am J Clin Pathol (2003) 0.97
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res (2006) 13.98
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol (2008) 10.29
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol (2009) 5.45
Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol (2009) 3.20
Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol (2009) 2.88
HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch (2010) 2.72
HER2 testing in gastric cancer: a practical approach. Mod Pathol (2012) 2.68
An international Ki67 reproducibility study. J Natl Cancer Inst (2013) 2.46
Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol (2009) 1.99
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat (2011) 1.89
Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol (2003) 1.87
[Ovarian epithelial dysplasia: Description of a dysplasia scoring scheme]. Ann Pathol (2011) 1.44
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch (2012) 1.34
Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol (2005) 1.27
Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal (2014) 1.20
Ontogeny, function, and peripheral homeostasis of regulatory T cells in the absence of interleukin-7. Blood (2006) 1.09
aHIF but not HIF-1alpha transcript is a poor prognostic marker in human breast cancer. Breast Cancer Res (2003) 1.08
Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist (2007) 1.05
Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study. Breast Cancer Res (2007) 1.01
Diagnosis and outcome of complete hydatidiform mole coexisting with a live twin fetus. Eur J Obstet Gynecol Reprod Biol (2005) 1.01
Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist (2008) 0.97
Comparative multi-methodological measurement of ERBB2 status in breast cancer. J Pathol (2004) 0.97
Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol (2008) 0.97
Leptin and leptin receptor involvement in cancer development: a study on human primary breast carcinoma. Oncol Rep (2008) 0.96
Epigenetic mechanisms of breast cancer: an update of the current knowledge. Epigenomics (2014) 0.95
Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases. Eur J Gastroenterol Hepatol (2012) 0.95
SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases. BMC Cancer (2013) 0.95
High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat (2005) 0.94
High inter-observer agreement in immunohistochemical evaluation of HER-2/neu expression in breast cancer: a multicentre GEFPICS study. Eur J Cancer (2006) 0.93
Diagnostic performance of one-step nucleic acid amplification for intraoperative sentinel node metastasis detection in breast cancer patients. Int J Cancer (2011) 0.93
Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer. Int J Cancer (2010) 0.93
The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur J Cancer (2012) 0.93
Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray. Virchows Arch (2006) 0.93
Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue. Breast Cancer Res Treat (2013) 0.92
Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial. Breast Cancer Res (2011) 0.91
Germline mutations of the E-cadherin gene in families with inherited invasive lobular breast carcinoma but no diffuse gastric cancer. Cancer (2011) 0.91
Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial. Breast Cancer Res Treat (2013) 0.90
Prognostic factors in early-stage leiomyosarcoma of the uterus. Int J Gynecol Cancer (2009) 0.89
Prognostic value of residual node involvement in operable breast cancer after induction chemotherapy. Breast Cancer Res Treat (2002) 0.89
Current status of HER2 testing. Oncology (2002) 0.88
Factors associated with liver steatosis and fibrosis in chronic hepatitis C patients. Gastroenterol Clin Biol (2004) 0.88
Does 99mTc-sestamibi uptake discriminate breast tumors? Cancer Invest (2004) 0.88
A new prognostic classification after primary chemotherapy for breast cancer: residual disease in breast and nodes (RDBN). Cancer J (2008) 0.88
Change in HER2 (ERBB2) gene status after taxane-based chemotherapy for breast cancer: polyploidization can lead to diagnostic pitfalls with potential impact for clinical management. Cancer Genet (2013) 0.86
Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs. Sarcoma (2008) 0.86
Epidermal growth factor receptor protein detection in head and neck cancer patients: a many-faceted picture. Clin Cancer Res (2012) 0.86
Ovarian epithelial dysplasia and prophylactic oophorectomy for genetic risk. Int J Gynecol Cancer (2009) 0.86
Single static view 99mTc-sestamibi scintimammography predicts response to neoadjuvant chemotherapy and is related to MDR expression. Int J Oncol (2002) 0.86
Risk of breast cancer by individual insulin use: an international multicenter study. Diabetes Care (2013) 0.85
Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition. Eur J Cancer (2008) 0.85
Giant mature ovarian cystic teratoma including more than 300 teeth. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2008) 0.84
Evolution of CFTR protein distribution in lung tissue from normal and CF human fetuses. Pediatr Pulmonol (2007) 0.83
Personalized medicine in oncology: where have we come from and where are we going? Pharmacogenomics (2013) 0.83
[Diagnostic pitfalls in mammary pathology. Case 7. Spindle-cell carcinoma of the breast or metaplastic carcinoma]. Ann Pathol (2009) 0.83
Loss of p16INK4A expression in low-grade ovarian serous carcinomas. Int J Gynecol Pathol (2011) 0.82
Is There a Relationship between Ovarian Epithelial Dysplasia and Infertility? Obstet Gynecol Int (2012) 0.82
Increase in morphine antinociceptive activity by a P-glycoprotein inhibitor in cisplatin-induced neuropathy. Neurosci Lett (2009) 0.82
Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer. Oncologist (2005) 0.81
O(6)-methylguanine-DNA methyl transferase gene expression and prognosis in breast carcinoma. Int J Oncol (2002) 0.81
Contrasted outcomes to gefitinib on tumoral IGF1R expression in head and neck cancer patients receiving postoperative chemoradiation (GORTEC trial 2004-02). Clin Cancer Res (2012) 0.81
Epigenetics of prostate cancer: distribution of histone H3K27me3 biomarkers in peri-tumoral tissue. OMICS (2014) 0.81
In vivo efficacy of melanoma internal radionuclide therapy with a 131I-labelled melanin-targeting heteroarylcarboxamide molecule. Int J Cancer (2013) 0.81
Lung cancer stem cell: fancy conceptual model of tumor biology or cornerstone of a forthcoming therapeutic breakthrough? J Thorac Oncol (2014) 0.80
Cost-effectiveness analysis of strategies for HER2 testing of breast cancer patients in France. Int J Technol Assess Health Care (2006) 0.80
Measurement of residual disease after neoadjuvant chemotherapy. J Clin Oncol (2008) 0.80
Mixture of hyaluronic acid, chondroitin 6 sulphate and dermatan sulphate used to completely regenerate bone in rat critical size defect model. J Craniomaxillofac Surg (2012) 0.79
Targeted radionuclide therapy of melanoma: anti-tumoural efficacy studies of a new 131I labelled potential agent. Int J Cancer (2009) 0.79
[Classification of preinvasive breast and carcinoma in situ: doubts, controversies, and proposal for new categorizations]. Bull Cancer (2004) 0.79
Instant-quality fluorescence in-situ hybridization as a new tool for HER2 testing in breast cancer: a comparative study. Histopathology (2013) 0.79
Dietary fat without body weight gain increases in vivo MCF-7 human breast cancer cell growth and decreases natural killer cell cytotoxicity. Mol Carcinog (2013) 0.78
Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer. Urology (2006) 0.77
[Modification of glycoconjugates during the carcinogenesis: the case of mammary carcinomas]. Bull Cancer (2004) 0.77
[HER2 gene amplification assay: is CISH an alternative to FISH?]. Ann Pathol (2003) 0.77
[The Fallopian tube odyssey: from the ovary to the tube. About high-grade serous ovarian carcinoma]. Bull Cancer (2013) 0.76
[Expression of epidermal growth factor receptor and its ligands in other malignant tumor pathologies]. Bull Cancer (2003) 0.75
[Extemporaneous histologic examination in infraclinical mammary lesions]. Bull Cancer (2003) 0.75
[Neoadjuvant treatment of breast cancer: implications for the pathologist]. Ann Pathol (2011) 0.75
Involvement of the multidrug resistance transporters in cisplatin-induced neuropathy in rats. Comparison with the chronic constriction injury model and monoarthritic rats. Eur J Pharmacol (2006) 0.75
[Docetaxel and gemcitabine combination in soft-tissue sarcomas treatment]. Bull Cancer (2007) 0.75
Sequential addition of an anthracycline-based regimen to docetaxel as neoadjuvant chemotherapy in patients with operable breast cancer. Clin Breast Cancer (2006) 0.75
[Diagnostic pitfalls in mammary pathology. Case 8. Breast metastases of a malignant melanoma]. Ann Pathol (2009) 0.75
Capillary permeability and extracellular volume fraction in uterine cervical cancer as patient outcome predictors: measurements by using dynamic MRI spin-lattice relaxometry. J Magn Reson Imaging (2008) 0.75
[An aggressive subtype of breast carcinoma]. Ann Pathol (2003) 0.75
[Recommendations and quality control in immunohistochemistry]. Ann Pathol (2009) 0.75
[Diagnostic immunohistochemistry of breast epithelial lesions]. Ann Pathol (2003) 0.75
[Place of anatomopathology in evaluation of response to neoadjuvant chemotherapy. Prognostic and predictive markers: example of breast cancer]. Bull Cancer (2006) 0.75
Hibernoma: a clinical model for exploring the role of brown adipose tissue in the regulation of body weight? J Clin Endocrinol Metab (2013) 0.75
[Detection of KRAS mutations: evolution or revolution for the pathologists?]. Ann Pathol (2008) 0.75
[Inflammatory breast carcinoma: towards molecular characterization?]. Ann Pathol (2003) 0.75
[Sentinel lymph node biopsy for breast cancer after neoadjuvant chemotherapy: influence of nodal status before treatment]. Bull Cancer (2006) 0.75
[A special issue on breast pathology]. Ann Pathol (2003) 0.75
[Lobular neoplasia]. Ann Pathol (2003) 0.75
Lung cancer: how to face the revolution? Target Oncol (2013) 0.75
[Breast cancer in Finistère, France: epidemiological description and tendencies over a 10-year period (2000-2009) according to pathology data]. Ann Pathol (2013) 0.75